Hepatic pathological characteristics and factors influencing alanine transaminase value below twice the upper limit of normal in patients with chronic hepatitis B.
10.3760/cma.j.cn501113-20230217-00062
- Author:
Xiao Hao WANG
1
,
2
,
3
;
Xiao Qing LIU
1
,
2
,
3
;
Da Chuan CAI
1
,
2
,
3
;
Peng HU
1
,
2
,
3
;
Hu LI
1
,
2
,
3
Author Information
1. Institute for Viral Hepatitis, Chongqing Medical University
2. Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education
3. Department of Infectious Disease, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
- Publication Type:Journal Article
- Keywords:
Antiviral therapy;
Chronic hepatitis B;
Fibrosis;
Hepatitis B virus;
Inflammation
- MeSH:
Male;
Humans;
Adult;
Female;
Hepatitis B, Chronic/complications*;
Alanine Transaminase;
Retrospective Studies;
Liver/pathology*;
Liver Cirrhosis/complications*;
Inflammation/pathology*;
Hepatitis B e Antigens
- From:
Chinese Journal of Hepatology
2023;31(5):483-488
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the hepatic pathological characteristics and factors influencing an alanine transaminase value below twice the upper limit of normal in patients with chronic hepatitis B (CHB) and further explore the optimal ALT threshold strategy for initiating antiviral therapy. Methods: Clinical data of treatment-naïve CHB patients who underwent liver biopsies from January 2010 to December 2019 were retrospectively collected. Multiple regression models were used to explore the ALT levels and significant risk of hepatic histological changes (≥G2/S2). Receiver operating characteristic curve was used to evaluate the value of different models in diagnosing liver tissue inflammation≥G2 or fibrosis ≥ S2. Results: A total of 447 eligible CHB patients, with a median age of 38.0 years and 72.9% males, were included. During ALT normalization, there was significant liver inflammation (≥G2) and fibrosis (≥S2) in 66.9% and 53.0% of patients, respectively. With an ALT rise of 1-2×ULN, the proportions of liver inflammation≥G2 and fibrosis≥S2 were 81.2% and 60.0%, respectively. After adjusting for confounding factors, higher ALT levels (> 29 U/L) were found to be associated with significant liver inflammation (OR: 2.30, 95% CI: 1.11 ~ 4.77) and fibrosis (OR: 1.84, 95% CI: 1.10 ~ 3.09). After the measurement of glutamyltransferase-platelet ratio (GPR), the proportion of CHB patients with≥G2/S2 was significantly reduced under different treatment thresholds of ALT standards, and in particular, the erroneous evaluation of liver fibrosis≥S2 was significantly improved (33.5% to 57.5%). Conclusion: More than half of CHB patients have a normal ALT or one within 2 × ULN, regardless of whether or not there is apparent inflammation and fibrosis. GPR can significantly improve the precise assessment of different conditions of treatment thresholds for the ALT value in CHB patients.
